Oxford Biomedica PLC
A global CDMO specializing in cell and gene therapy and viral vector manufacturing.
OXB | IL
Overview
Corporate Details
- ISIN(s):
- GB00BDFBVT43
- LEI:
- 213800S1GVQNXQ15K851
- Country:
- United Kingdom
- Address:
- WINDRUSH COURT, OX4 6LT OXFORD
- Website:
- https://www.oxb.com/
- Sector:
- Manufacturing
Description
Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-03-09 16:17 |
PROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
|
English | 120.2 KB | ||
| 2018-03-01 10:33 |
Total Voting Rights
|
English | 14.0 KB | ||
| 2018-02-28 08:15 |
Hardman & Co Res: BIVV deal establishes structure
|
English | 12.8 KB | ||
| 2018-02-23 15:03 |
Director/PDMR Shareholding
|
English | 17.7 KB | ||
| 2018-02-20 15:12 |
Holdings in Company
|
English | 68.2 KB | ||
| 2018-02-15 08:00 |
Bioverativ Collaboration and Licence Agreement
|
English | 15.9 KB | ||
| 2018-02-01 12:28 |
Total Voting Rights
|
English | 13.9 KB | ||
| 2018-01-23 10:45 |
£3 million Innovate UK grant
|
English | 14.7 KB | ||
| 2018-01-23 10:30 |
Director Dealings / Market Share Purchase
|
English | 17.7 KB | ||
| 2018-01-17 08:00 |
Kymriah receives Priority Review for adult DLBCL
|
English | 14.0 KB | ||
| 2018-01-09 10:54 |
BLOCK LISTING RETURN
|
English | 23.1 KB | ||
| 2018-01-03 14:33 |
Holding(s) in Company
|
English | 65.6 KB | ||
| 2018-01-02 10:49 |
Total Voting Rights
|
English | 14.0 KB | ||
| 2017-12-31 01:00 |
2017 Annual Report and Accounts
|
English | 5.3 MB | ||
| 2017-12-20 12:22 |
Director Dealings / Market Share Purchase
|
English | 17.7 KB |
Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Oxford Biomedica PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
